RegAlert2015-02-12
Added · Updated
SEC Division of Corporation Finance no-action letter: Mylan Inc.
Mylan Inc. and New Moon B.V. request staff advice regarding succession-related matters under the Securities Act of 1933 and the Securities Exchange Act of 1934 in connection with a transaction where New Moon B.V. becomes a holding company for Mylan and Abbott Laboratories' developed markets specialty and branded generics business. The entities intend for New Moon B.V. to be converted into a public limited liability company renamed Mylan N.V., with its ordinary shares listed on NASDAQ under the ticker symbol MYL. Mylan plans to deregister its common stock under Section 12 of the Exchange Act and file Form 15 to suspend reporting obligations, while New Mylan will assume reporting responsibilities under Section 13(a) as a successor entity.
SEC published 7 documents in the last 30 days — get each new one by email the day it lands.
1000 Mylan Boulevard
Canonsburg, PA 15317 USA
Phone 724.514.1800
Fax 724.514.1870
Web mylan.com
February 12, 2015
Office of Chief Counsel
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Mylan Inc. and New Moon B.V.
Dear Sir or Madam:
I am writing on behalf of Mylan Inc., a Pennsylvania corporation (“Mylan”), and New Moon B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) organized and existing under the laws of the Netherlands (“New Mylan”), to request advice of the staff of the Office of Chief Counsel of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to a number of successionrelated matters under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The matters relate to the proposed transaction (the “Transaction”) in which Mylan and the non-U.S. developed markets specialty and branded generics business (the “Business”) of Abbott Laboratories (“Abbott”) will become held by New Mylan, a new holding company organized in the Netherlands that will be converted into a public limited liability company (naamloze vennootschap) and renamed Mylan N.V. at or prior to the completion of the Transaction. Background Information
- Mylan
Mylan is a publicly held Pennsylvania corporation and a leading global pharmaceutical company. Mylan, through its subsidiaries, develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. In addition to organic growth, Mylan evaluates and, where appropriate, executes on acquisitions as a strategic part of its future growth. Mylan prioritizes opportunities that complement and further diversify its platform, whether such opportunities are effected through asset or stock purchases, joint ventures, licenses, or acquisitions of other companies. The shares of Mylan common stock, par value $0.50 per share (“Mylan common stock”), are registered under Section 12(b) of the Exchange Act and are listed on
Read the rest free, and get an email when SEC publishes again
Lineage: In force
Source: Securities and Exchange Commission — original document · Summary generated with machine assistance and reviewed before publication; the authoritative text is the regulator's original document. How RegAlert works
More like this from SEC
SEC published 7 documents in the last 30 days. We email you each new one the day it's published.